Investigating how vasopressor therapy affects kidney blood flow in septic shock patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study examines the impact of vasopressor therapy, specifically vasopressin and angiotensin II, on renal microcirculatory perfusion in patients experiencing septic shock and acute kidney injury. It aims to understand the relationship between these therapies and kidney blood flow abnormalities that occur despite normal overall blood circulation. Patients will be monitored within 48 hours of intensive care admission, focusing on those requiring norepinephrine infusion. The findings may provide insights into the pathophysiology of septic acute kidney injury and potential therapeutic strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Within 48 hours of intensive care admission
* Evidence of suspected or confirmed infection
* Sequential Organ Failure (SOFA) score increase of 2 or more (assuming a baseline of 0 if no previous measures)
* Requirement for norepinephrine infusion as the sole vasopressor agent in a dose of \>0.1mcg/kg/min
* Lactate \>2mmol/L at any stage prior to randomisation

Exclusion Criteria:

* Known intolerance to Sonovue™ contrast medium, vasopressin or angiotensin II
* Patients receiving other vasoactive drugs in addition to norepinephrine
* Patients with known chronic kidney disease (CKD) stage 4 or 5 (baseline glomerular filtration rate (GFR) \<30mls/min)
* Patients receiving extra corporal membrane oxygenation (ECMO)
* Patients with acute occlusive coronary syndromes requiring intervention
* Patients with mesenteric ischaemia
* Patients with a history or presence of aortic dissection or abdominal aortic aneurysm
* Patients with Raynaud's syndrome or acute vaso-occlusive conditions
* Pregnancy

Where it's running

• King's College Hospital
  London, United Kingdom Recruiting

Study contacts

• Study coordinator: Sam Hutchings
• Email: sam.hutchings@nhs.net
• Phone: 02032994957

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Reducing Endotoxin Burden in Septic Shock Patients on CRRT with the oXiris Filter

  This trial tests whether using the oXiris hemofilter during continuous kidney replacement helps lower endotoxin levels in adults with septic shock who need CRRT.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07807410

• Can Timps2 and IGFBP7 Urine Test Help Flag High-Risk AKI in Septic Shock Patients

  This study tests whether a urine test called Nephrocheck, which measures TIMP2 and IGFBP7, can identify septic shock patients at higher risk of progressing to severe acute kidney injury.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens · NCT03547414

• Adjunctive Fludrocortisone in Septic Shock on Hydrocortisone

  In septic shock, this trial tests whether adding fludrocortisone (50 mcg or 100 mcg daily) to hydrocortisone improves survival and recovery compared with placebo.

  Recruiting at 2 sites Phase 3 The George Institute · Penrith, New South Wales and 7 other locations · NCT07898462

• Remote Ischemic Preconditioning at Different Times After Heart Valve Surgery

  This study tests whether applying brief, controlled blood-flow restrictions to a limb at different times after heart valve surgery can help protect organs and reduce complications like kidney injury.

  Recruiting Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT07888634

• Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes

  This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07868666

• Non-invasive hemodynamic guidance for sepsis care on medical wards

  This trial tests whether guiding fluid and vasopressor therapy for sepsis using non-invasive hemodynamic measurements works better than standard care.

  Recruiting at 2 sites Regione del Veneto - AULSS n. 7 Pedemontana · Pisa, Pisa and 1 other locations · NCT07863323

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.